Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827345 | 0.85 | ESR1 (0.56) | ESR1ESR2KCNN4TAAR1MAPK1 | |
| SCHEMBL23234255 | 0.82 | ESR1 (0.40) | ESR1ESR2KCNN4TAAR1KIF11 | |
| SCHEMBL15757756 | 0.82 | ESR1 (0.47) | ESR1ESR2KCNN4TAAR1KIF11 | |
| SCHEMBL29210399 | 0.79 | ESR1 (0.38) | ESR1ESR2KCNN4TAAR1KIF11 | |
| SCHEMBL8804043 | 0.78 | KIF11 (0.38) | ESR1ESR2KIF11TSHRALDH1A1 | |
| SCHEMBL11297940 | 0.76 | ESR1 (0.48) | ESR1ESR2KCNN4TAAR1MAPK1 | |
| SCHEMBL285366 | 0.76 | ESR1 (0.50) | ESR1ESR2KCNN4TAAR1KIF11 | |
| SCHEMBL2086206 | 0.76 | TAAR1 (0.54) | ESR1ESR2KCNN4TAAR1KIF11 | |
| SCHEMBL27684700 | 0.76 | TAAR1 (0.48) | KCNN4TAAR1KIF11TSHRALDH1A1 | |
| SCHEMBL3805520 | 0.76 | ALDH1A1 (0.48) | ESR1ESR2KCNN4TAAR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012413-B2 | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-04-21 | — | — | US | disclosed |
| US-20120214754-A1 | FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-23 | — | — | US | disclosed |
| EP-2464667-A2 | N-ACYLATED OCTASACCHARIDES ACTIVATING FGFS RECEPTORS, THEIR SYNTHESIS AND THEIR THERAPEUTICAL APPLICATION | SANOFI (FR) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011018588-A2 | FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | WO | disclosed |
| EP-2007760-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007108569-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-09-27 | — | — | WO | disclosed |
| US-5508273-A | ARALKYLPHOSPHONATES FOR OSTEOPOROSIS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214754-A1 | FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | FGFR1, FGF2, FGFR3 | ESR1 2717/4885ESR2 1702/4885KCNN4 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.